ERBB2 and neoplasm: Whether the HER2-signaling pathway of tumor growth is involved in the initiation and progression to CSCs is unknown; cluster of differentiation (CD)44highCD24lowHER2low breast CSCs respond poorly to trastuzumab alone, but the combination of trastuzumab and pertuzumab is effective against these cells [195].